The DOI matches its Crossref record.
Relationship between beta-lactamase production, outer membrane protein and penicillin-binding protein profiles on the activity of carbapenems against clinical isolates of Acinetobacter baumannii
Abstract
Twenty blood isolates of Acinetobacter baumannii were studied, representing eight pulsed-field gel electrophoresis patterns and all different antimicrobial susceptibility patterns observed during 1995-97 at the University Hospital Virgen Macarena, Seville, Spain. The MIC(90)s (mg/L) of imipenem and meropenem decreased from 16 to 0.5 and from 8 to 4, respectively, in the presence of BRL 42715 (BRL) but not clavulanic acid. Hydrolysing activity (nmol/min/mg) of bacterial supernatants against cefaloridine ranged from 8.8 to 552.3 for A. baumannii type I (imipenem MICs < or = 2), which expressed only a beta-lactamase of pI > or = 9, and from 12.3 to 1543.5 for A. baumannii type II (imipenem MICs > or = 4), which expressed a beta-lactamase of pI > or = 9 and two others of pI 6.3 and 7. The hydrolysing activities of A. baumannii type II against imipenem, meropenem and oxacillin were higher than those observed for A. baumannii type I. Ten outer membrane protein (OMP) profiles (A. baumannii types I and II) were visualized on 10% SDS-PAGE gels with 6 M urea, whereas only five OMP profiles (A. baumannii types I and II) were differentiated in 12% SDS-PAGE gels. Five A. baumannii with OMP profile type B, characterized by the absence of a 22.5 kDa OMP, were resistant to meropenem and/or imipenem. Twelve penicillin-binding protein (PBP) patterns were observed. PBP patterns of A. baumannii type II were characterized by the absence of a 73.2 kDa band (PBP 2). We concluded that production of beta-lactamases of pI 6.3 and 7.0 and reduced expression of PBP 2 are the most frequently observed mechanisms of resistance to carbapenems. In some isolates, loss of a 22.5 kDa OMP is also related to resistance to carbapenems.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Acinetobacter baumannii : Emergence of a Successful Pathogen
Peleg, A. Y., Seifert, H., & Paterson, D. L. (2008) · Clinical Microbiology Reviews · doi:10.1128/cmr.00058-07 · Cited by 3,316
Carbapenems: Past, Present, and Future
Papp-Wallace, K. M., Endimiani, A., Taracila, M. A., & Bonomo, R. A. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00296-11 · Cited by 1,502
Tamma, P. D., Heil, E. L., Justo, J. A., Mathers, A. J., Satlin, M. J., & Bonomo, R. A. (2024) · Clinical Infectious Diseases · doi:10.1093/cid/ciae403 · Cited by 1,191
Clinical and Pathophysiological Overview of Acinetobacter Infections: a Century of Challenges
Wong, D., Nielsen, T. B., Bonomo, R. A., Pantapalangkoor, P., Luna, B., & Spellberg, B. (2017) · Clinical Microbiology Reviews · doi:10.1128/cmr.00058-16 · Cited by 1,170
Global Challenge of Multidrug-Resistant Acinetobacter baumannii
Perez, F., Hujer, A. M., Hujer, K. M., Decker, B. K., Rather, P. N., & Bonomo, R. A. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01464-06 · Cited by 1,139
Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology
Poirel, L., & Nordmann, P. (2006) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2006.01456.x · Cited by 1,051
Bacterial Resistance to β-Lactam Antibiotics: Compelling Opportunism, Compelling Opportunity
Fisher, J. F., Meroueh, S. O., & Mobashery, S. (2005) · Chemical Reviews · doi:10.1021/cr030102i · Cited by 913
Acinetobacter baumannii Antibiotic Resistance Mechanisms
Kyriakidis, I., Vasileiou, E., Pana, Z. D., & Tragiannidis, A. (2021) · Pathogens · doi:10.3390/pathogens10030373 · Cited by 678
Multidrug resistant Acinetobacter
Manchanda, V., Sanchaita, S., & Singh, N. (2010) · Journal of Global Infectious Diseases · doi:10.4103/0974-777x.68538 · Cited by 555
Walther-Rasmussen, J., & Høiby, N. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki482 · Cited by 495
Porins, efflux pumps and multidrug resistance in Acinetobacter baumannii
Vila, J., Martí, S., & Sánchez-Céspedes, J. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl509 · Cited by 436
Multidrug-resistant Acinetobacter baumannii: mechanisms of virulence and resistance
Gordon, N. C., & Wareham, D. W. (2010) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2009.10.024 · Cited by 378
The Acinetobacter baumannii Oxymoron: Commensal Hospital Dweller Turned Pan-Drug-Resistant Menace
Roca, I., Espinal, P., Vila-Farrés, X., & Vila, J. (2012) · Frontiers in Microbiology · doi:10.3389/fmicb.2012.00148 · Cited by 363
Tackling Threats and Future Problems of Multidrug-Resistant Bacteria
Medina, E., & Pieper, D. H. (2016) · Current Topics in Microbiology and Immunology · doi:10.1007/82_2016_492 · Cited by 356
Acinetobacter baumannii: Evolution of Antimicrobial Resistance—Treatment Options
Murray, G., Peleg, A., & Doi, Y. (2015) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0034-1398388 · Cited by 316
Acinetobacter baumannii Resistance: A Real Challenge for Clinicians
Vázquez-López, R., Solano-Gálvez, S. G., Juárez Vignon-Whaley, J. J., Abello Vaamonde, J. A., Padró Alonzo, L. A., Rivera Reséndiz, A., Muleiro Álvarez, M., Vega López, E. N., Franyuti-Kelly, G., Álvarez-Hernández, D. A., et al. (2020) · Antibiotics · doi:10.3390/antibiotics9040205 · Cited by 296
Mussi, M. A., Limansky, A. S., & Viale, A. M. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.4.1432-1440.2005 · Cited by 276
Abdelkader, M. M., Aboshanab, K. M., El-Ashry, M. A., & Aboulwafa, M. M. (2017) · PLOS ONE · doi:10.1371/journal.pone.0171349 · Cited by 44
Metadata
- Authors
- Fernandez-Cuenca, F.
- Venue
- Journal of Antimicrobial Chemotherapy
- Publisher
- Oxford University Press (OUP)
- Published
- 2003-01-28
- Volume
- 51
- Issue
- 3
- Pages
- 565-574
- ISSN
- 0305-7453 (ISSN-L)
- 1460-2091
- OpenAlex
- W2114686855
- Cited by
- 229
- References
- 0
- FWCI
- 6.12
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.